Loading patent…
AssigneesFundació Institut de Recera Biomèdica (IRB Barcelona), Institució Catalana De Recerca I Estudis AvançAts
InventorsRoger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
Estimating the term…
The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.
An in vitro method for diagnosing a subject with an increased risk of bone metastasis or recurrence of a triple negative (including basal-like) breast cancer in a subject suffering said cancer and treating said subject to inhibit or prevent said bone metastasis or recurrence, comprising detecting amplification and/or gain of the c-MAF gene in a sample of said subject relative to a reference gene copy number, wherein an amplification and/or gain of the c-MAF gene with respect to said reference gene copy number is indicative of increased risk of developing bone metastasis or recurrence, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject with an increased risk of bone metastasis or recurrence.
An in vitro method for diagnosing a subject with an increased risk of bone metastasis or recurrence of a triple negative (including basal-like) breast cancer in a subject suffering said cancer and treating said subject to inhibit or prevent said bone metastasis or recurrence, comprising detecting translocation of the c-MAF gene in a sample of said subject, wherein a translocation of the c-MAF gene is indicative of an increased risk of developing bone metastasis or recurrence, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject with an increased risk of bone metastasis or recurrence.
An in vitro method for predicting the clinical outcome of a subject suffering triple negative (including basal-like) breast cancer and further treating said subject, comprising detecting amplification and/or gain of the c-MAF gene in a sample of said subject relative to a reference gene copy number, wherein an amplification and/or gain of the c-MAF gene with respect to said reference gene copy number is indicative of a poor clinical outcome, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject.
An in vitro method for predicting the clinical outcome of a subject suffering from triple negative (including basal-like) breast cancer and further treating said subject comprising detecting translocation of the c-MAF gene in a sample of said subject, wherein a translocation of the c-MAF gene is indicative of a poor clinical outcome, and administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to prevent and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR-5 antagonist and/or Radium-223, and/or an agent capable of avoiding and/or preventing bone degradation to said subject.
Dependencies are inferred from the claim text.